Compensation award — excluded from discretionary-purchase analysis.
Loading…
Traded Feb 2, 2026 · Filed Feb 3, 2026
Biogen's Head of Development sold $134K of Biogen shares. Nobody planned it ahead of time.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell
open market sale
Code S — open-market or private sale
~$134,116
Shares × reported transaction price
19 days after results of Jan 14, 2026, 4 days before results of Feb 6, 2026
Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results
Closed at $179.09 on Feb 2, 2026, within 5% of its 52-week high, after a 4% rise over the previous 30 trading days
52-week range $113.38 (Apr 10, 2025) to $187.62 (Jan 9, 2026), 89% of the way up, from 251 adjusted closes. 30 trading days earlier: $172.10 on Dec 17, 2025. Describes the past only, not a forecast
None found in footnotes
Only flagged when a footnote says so; never inferred
A securities lawsuit naming the company as a defendant was filed on Oct 23, 2024 in the U.S. District Court, D. Massachusetts. A filing is an allegation, not a finding.
Gray v. Biogen Inc., docket 1:24-cv-12691, via CourtListener (court records). Nature of suit 850, company named as first defendant
| After | Stock | S&P 500 | Difference |
|---|---|---|---|
| 7 days | +3.1% | +0.8% | +2.3% |
| 30 days | -0.3% | -2.0% | +1.7% |
| 90 days | +2.0% | +5.5% | -3.5% |
| 180 days | +8.8% | +10.4% | -1.6% |
Past results only. Not a forecast.
Compensation award — excluded from discretionary-purchase analysis.
Compensation award — excluded from discretionary-purchase analysis.
20K → 20K shares held
Biogen's Head of Pharm Ops and Tech spent $585 of their very own money to buy Biogen shares.
